Patient Lifestyle

Winnipeg technician conference a resounding success.

Greater efforts may be needed in Canada to combat human papillomavirus (HPV)-related head and neck cancers, according to researchers at the University of Ottawa.

Rilpivirine is the fifth NNRTI to be marketed in Canada.

Author drafting new guidelines doubts restrictions, including on opioids marketing, would reduce diversion

Helping patients to delay progression and preserve vision.

While finding may not be surprising, the question becomes how to intervene to help patients

Concerns that the addition of insulin to type 2 diabetes patients already on the new injectable glucagon-like peptide (GLP-1) liraglutide could result in weight gain may not be warranted, researchers suggested here.